Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial.
Kobayashi M, Huttin O, Ferreira JP, Duarte K, González A, Heymans S, Verdonschot JAJ, Brunner-La Rocca HP, Pellicori P, Clark AL, Petutschnigg J, Edelmann F, Cleland JG, Rossignol P, Zannad F, Girerd N; HOMAGE Trial Committees and Investigators. Kobayashi M, et al. Among authors: petutschnigg j. Eur J Heart Fail. 2023 Aug;25(8):1284-1289. doi: 10.1002/ejhf.2859. Epub 2023 Apr 26. Eur J Heart Fail. 2023. PMID: 37062878 Free article.
Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial.
Petutschnigg J, Ferreira JP, Holzendorf V, Trippel TD, Hashemi D, Wachter R, Herrmann-Lingen C, Hasenfuß G, Zannad F, Pieske B, Edelmann F. Petutschnigg J, et al. Eur J Heart Fail. 2020 Mar;22(3):559-561. doi: 10.1002/ejhf.1723. Epub 2020 Jan 7. Eur J Heart Fail. 2020. PMID: 31912594 Free article. No abstract available.
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.
Pellicori P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B, Girerd N, González A, Clark AL, Cosmi F, Staessen JA, Heymans S, Latini R, Rossignol P, Zannad F, Cleland JGF. Pellicori P, et al. Among authors: petutschnigg j. Eur J Heart Fail. 2020 Sep;22(9):1711-1723. doi: 10.1002/ejhf.1716. Epub 2020 Jan 16. Eur J Heart Fail. 2020. PMID: 31950604 Free article. Clinical Trial.
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP, Mamas MA, Clark AL, Edelmann F, Pieske B, Khan J, McDonald K, Rouet P, Staessen JA, Mujaj B, González A, Diez J, Hazebroek M, Heymans S, Latini R, Grojean S, Pizard A, Girerd N, Rossignol P, Collier TJ, Zannad F; HOMAGE Trial Committees and Investigators. Cleland JGF, et al. Among authors: petutschnigg j. Eur Heart J. 2021 Feb 11;42(6):684-696. doi: 10.1093/eurheartj/ehaa758. Eur Heart J. 2021. PMID: 33215209 Free PMC article. Clinical Trial.
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, Brunner-La-Rocca HP, Clark AL, Cosmi F, Cuthbert J, Díez J, Edelmann F, Girerd N, González A, Grojean S, Hazebroek M, Khan J, Latini R, Mamas MA, Mariottoni B, Mujaj B, Pellicori P, Petutschnigg J, Pieske B, Rossignol P, Rouet P, Staessen JA, Cleland JGF, Heymans S, Zannad F; HOMAGE (Heart Omics in AGEing) Consortium. Ferreira JP, et al. Among authors: petutschnigg j. JACC Heart Fail. 2021 Apr;9(4):268-277. doi: 10.1016/j.jchf.2020.11.010. Epub 2021 Feb 3. JACC Heart Fail. 2021. PMID: 33549556 Free article. Clinical Trial.
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
Ferreira JP, Collier T, Clark AL, Mamas MA, Rocca HB, Heymans S, González A, Ahmed FZ, Petutschnigg J, Mujaj B, Cuthbert J, Rouet P, Pellicori P, Mariottoni B, Cosmi F, Edelmann F, Thijs L, Staessen JA, Hazebroek M, Verdonschot J, Rossignol P, Girerd N, Cleland JG, Zannad F. Ferreira JP, et al. Among authors: petutschnigg j. Eur Heart J Cardiovasc Pharmacother. 2022 Feb 16;8(2):149-156. doi: 10.1093/ehjcvp/pvab031. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 33822033 Free article. Clinical Trial.
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.
Verdonschot JAJ, Ferreira JP, Pellicori P, Brunner-La Rocca HP, Clark AL, Cosmi F, Cuthbert J, Girerd N, Mariottoni B, Petutschnigg J, Rossignol P, Cleland JGF, Zannad F, Heymans SRB; HOMAGE “Heart Omics in AGEing” consortium. Verdonschot JAJ, et al. Among authors: petutschnigg j. Cardiovasc Diabetol. 2021 Aug 9;20(1):163. doi: 10.1186/s12933-021-01357-9. Cardiovasc Diabetol. 2021. PMID: 34372849 Free PMC article. Clinical Trial.
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial.
Ravassa S, López B, Ferreira JP, Girerd N, Bozec E, Pellicori P, Mariottoni B, Cosmi F, Hazebroek M, Verdonschot JAJ, Cuthbert J, Petutschnigg J, Moreno MU, Heymans S, Staessen JA, Pieske B, Edelmann F, Clark AL, Cleland JGF, Zannad F, Díez J, González A; HOMAGE Trial Committees and Investigators. Ravassa S, et al. Among authors: petutschnigg j. Eur J Heart Fail. 2022 Feb;24(2):321-331. doi: 10.1002/ejhf.2394. Epub 2021 Dec 9. Eur J Heart Fail. 2022. PMID: 34841615 Free article. Clinical Trial.
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial.
Verdonschot JAJ, Ferreira JP, Pizard A, Pellicori P, Brunner La Rocca HP, Clark AL, Cosmi F, Cuthbert J, Girerd N, Waring OJ, Henkens MHTM, Mariottoni B, Petutschnigg J, Rossignol P, Hazebroek MR, Cleland JGF, Zannad F, Heymans SRB; HOMAGE “Heart Omics in AGEing” Consortium. Verdonschot JAJ, et al. Among authors: petutschnigg j. J Card Fail. 2022 May;28(5):778-786. doi: 10.1016/j.cardfail.2021.12.005. Epub 2021 Dec 18. J Card Fail. 2022. PMID: 34933097 Free article. Clinical Trial.
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
Ferreira JP, Verdonschot JAJ, Girerd N, Bozec E, Pellicori P, Collier T, Mariottoni B, Cosmi F, Hazebroek M, Cuthbert J, Petutschnigg J, Heymans S, Staessen JA, Pieske B, Edelman F, Clark AL, Díez J, González A, Rossignol P, Cleland JG, Zannad F. Ferreira JP, et al. Among authors: petutschnigg j. Eur J Heart Fail. 2022 May;24(5):771-778. doi: 10.1002/ejhf.2455. Epub 2022 Mar 5. Eur J Heart Fail. 2022. PMID: 35199421 Free article. Clinical Trial.
28 results